|
Patent landscape, scope, and claims: |
United States Patent 5,446,194 Scope and Claim Landscape: Formula I Acrylamide Derivatives, Nitro/Cyano Substitution, and Downstream US IP Risk
United States Patent 5,446,194 covers a defined set of substituted cinnamoyl/acrylamide-type compounds of a “Formula I” scope driven by (i) nitro or cyano aromatic substituents, (ii) cyano/alkylcarbonyl choices at a key ring-adjacent position, and (iii) an acrylamide N-substitution pattern (carbamoyl/unsubstituted or substituted carbamoyl; hydroxyalkyl; alkyl esters and salts). Claim 3 and Claim 4 lock in specific, enumerated examples within that broader genus, including N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and three narrower exemplars with 2-cyano and the 3,4-dihydroxy-5-nitro motif.
What exactly is protected in US 5,446,194?
- A genus of substituted acrylamide compounds by structural formula (Claim 1).
- Selected subgenus limitations tied to R4 and R5 (Claim 2).
- At least one specific compound species plus a three-member species set (Claims 3 and 4).
What do claims 1-4 of US Patent 5,446,194 actually cover (scope in plain structural terms)?
Core protected scaffold (Claim 1):
A “compound according to formula I” with:
- Aromatic ring substitution:
- X is nitro or cyano.
- The ring also contains R3, a substitution that itself includes an additional substituent definition (R4 and R5), embedded in the broader formula description.
- Alkyl/amide nitrogen substitution (R1/R2):
- R1 and R2 independently are:
- hydrogen; or
- carbamoyl substituted by C1–C4 alkyl; or
- alkylcarbonyl with C2–C5; or
- phenyl carbonyl.
- Additional functional block (R3 → R4 and R5):
- R4 is cyano or alkylcarbonyl (C2–C5).
- R5 is carbamoyl either:
- unsubstituted; or
- substituted with C1–C8 alkyl; or
- substituted with hydroxyalkyl (C1–C8);
- plus pharmaceutically acceptable esters and salts of the resulting compounds.
Key legal consequence of Claim 1:
Even without parsing every bond in the rendering, Claim 1 is a genus claim with multiple independent “option slots” (R1/R2, X, R4, R5). That means:
- infringement can occur by falling within the defined structural ranges even if the exact examples in Claims 3-4 are not used.
- any competitor product must avoid at least one limiting element in the defined structural constraints to stay outside literal claim coverage.
Which specific compounds are explicitly claimed in US 5,446,194 (species claims 3 and 4)?
Claim 3 (specific species):
- N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide
This is a direct “species anchor” within the genus.
Claim 4 (three enumerated species):
- 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide (no N-substituted descriptor is included in the claim text you provided, implying the N pattern aligns with the formula definitions for the specific case)
- N,N-dimethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide
- N-isopropyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-acrylamide
Claim 3 + 4 effect:
- The patent provides stronger enforcement leverage on these exact structures because they are spelled out.
- Competitors seeking design-around often target the nitro vs cyano choice and/or the N-substitution class. Claims 3-4 show that at least the 3,4-dihydroxy-5-nitrophenyl + 2-cyano motif plus varied N-alkylation is within the claim set.
How do R1/R2 and R4/R5 choices constrain infringement (where does the claim “turn off”)?
Critical infringement determinants embedded in Claim 1:
-
X must be nitro or cyano.
- If the product has a different substituent in the corresponding aromatic position (for example, halogens without cyano/nitro, or unsubstituted), it does not meet the X limitation.
-
R4 must be cyano or C2–C5 alkylcarbonyl.
- Moving to a different functional group at the R4 position, such as amide, sulfonyl, hydroxyl, halogen, or higher-carbon-number acyl can fall outside.
-
R5 must be “carbamoyl” with specific substitution limits or hydroxyalkyl limits.
- R5 is restricted by the requirement that it is carbamoyl (unsubstituted or substituted with C1–C8 alkyl or C1–C8 hydroxyalkyl) and that esters/salts are included.
- Substitutions that replace “carbamoyl” with non-carbamoyl amide groups do not literally satisfy R5.
-
R1/R2: N-substitution space is limited to defined carbamoyl or carbonyl choices.
- The claim includes hydrogen; carbamoyl substituted by C1–C4 alkyl; alkylcarbonyl of C2–C5; and phenylcarbonyl.
- The enumerated example compounds in Claims 3-4 demonstrate N-substitution can be diethyl, dimethyl, and isopropyl within the claimed architecture.
Design-around logic that follows from Claim 1’s “option slots”:
- Altering any one slot so it no longer fits the required set membership (nitro/cyano, cyano/C2–C5 alkylcarbonyl, carbamoyl with C1–C8 alkyl or C1–C8 hydroxyalkyl, etc.) can remove literal infringement.
- Non-literal infringement analysis (doctrine of equivalents) is not addressed here because the request is claim scope and landscape; the claim drafting itself shows multiple exact structural predicates.
What is the practical effect of Claim 2’s subgenus restriction (R4=cyano, R5 limited carbamoyl)?
Claim 2 narrows Claim 1 to:
- R4 is cyano
- R5 is carbamoyl that is either:
- unsubstituted, or
- substituted with C1–C3 alkyl
This is a tighter range focused on the most straightforward R4 (cyano) and smaller R5 alkyl variants (C1–C3). The claim set therefore has a hierarchy:
- Claim 1: broad genus
- Claim 2: narrower genus/subgenus
- Claims 3-4: specific species within that narrower zone (at least in part)
How does Claim 1’s breadth compare with Claims 3-4 (genus-to-species enforceability)?
Enforcement leverage profile:
- Species claims (3,4)
- easier to match because the structures are explicitly listed.
- Genus claim (1)
- covers potentially many additional compounds beyond those named.
- can support broad injunction and discovery requests if an accused product sits inside multiple “option slots.”
Risks for defendants:
If an accused compound matches X=nitro and the 2-cyano and 3,4-dihydroxy pattern shown in Claims 3-4, and if the N-substitution and carbamoyl substitution fit the R1/R2 and R5 constraints, it will likely be difficult to argue non-infringement on literal grounds.
What patent landscape can be concluded from only the claim text provided for US 5,446,194?
No additional landscape elements (other related patents, continuation families, priority data, prosecution history, assignees, citation chains, litigation, Orange Book listings, or FDA linkage) can be produced from the text you supplied. Only the scope implied by the four claims can be analyzed with precision.
Accordingly, the deliverable below is restricted to:
- claim scope structure analysis of US 5,446,194 as written in Claims 1–4; and
- a claim-based infringement map for key variable positions.
Infringement map: which structural modifications most directly reduce coverage under US 5,446,194?
A. Aromatic substituent switch (X)
- Avoid aromatic-position substituent limited to nitro or cyano (X).
- Moving to other groups at that position is the most immediate “slot” escape.
B. R4 replacement
- Avoid R4 being cyano or C2–C5 alkylcarbonyl.
- Replacing with other functional groups can remove literal coverage.
C. R5 replacement
- Avoid R5 being carbamoyl with the specified substitution (unsubstituted; C1–C8 alkyl; or C1–C8 hydroxyalkyl).
- Using other amide types, ureas that do not match “carbamoyl” definition, or carbamoyl with substituents outside C1–C8 limits can remove literal coverage.
D. N-substitution / R1-R2 options
- Avoid N-substitution that fits the defined set for R1/R2:
- hydrogen
- carbamoyl substituted by C1–C4 alkyl
- C2–C5 alkylcarbonyl
- phenylcarbonyl
- Moving to other carbonyl types or other heteroatom-containing substitutions outside these categories reduces the chance of literal infringement.
Which search terms best capture how competitors might test design-arounds for US 5,446,194?
- “2-cyano 3-(3,4-dihydroxy-5-nitrophenyl)acrylamide N-substitution”
- “carbamoyl hydroxyalkyl C1-C8 acrylamide nitro cyano”
- “R4 cyano alkylcarbonyl C2-C5 substitution design around”
- “pharmaceutically acceptable salts esters scope acrylamide formula I”
Key Takeaways
- US 5,446,194 Claim 1 is a formula-based genus claim that restricts infringement through multiple categorical structural slots: X (nitro/cyano), R4 (cyano or C2–C5 alkylcarbonyl), R5 (carbamoyl with specified C1–C8 alkyl or C1–C8 hydroxyalkyl substitution), and R1/R2 (limited hydrogen/carbamoyl-alkyl/carbonyl/phenylcarbonyl classes).
- Claims 3 and 4 explicitly name multiple species anchored to the 2-cyano + 3,4-dihydroxy-5-nitrophenyl + acrylamide motif with defined N-substitution patterns (diethyl, dimethyl, isopropyl, and a third enumerated member).
- Claim 2 narrows the genus to R4=cyano and R5=carbamoyl with unsubstituted or C1–C3 alkyl substitution.
- The cleanest design-around paths, based on claim text alone, are structural changes that break at least one of the defined slot memberships (nitro/cyano, cyano/C2–C5 alkylcarbonyl, carbamoyl C1–C8 hydroxyalkyl or C1–C3 small alkyl on the restricted subgenus, and the allowed R1/R2 carbonyl class).
FAQs
1) Does US 5,446,194 require both nitro and cyano substitution to infringe?
No. Claim 1 allows X to be nitro or cyano.
2) If a compound replaces R4=cyano with an amide group, is it outside the claim?
A literal reading indicates it is outside because Claim 1 limits R4 to cyano or C2–C5 alkylcarbonyl.
3) Are esters and salts explicitly included in US 5,446,194?
Yes. Claim 1 states “pharmaceutically acceptable esters and salts thereof.”
4) Are N-substituted variants like dimethyl and diethyl on the acrylamide nitrogen covered?
Yes. Claims 3 and 4 include N,N-diethyl and N,N-dimethyl species.
5) Is the protection limited to the three species in Claim 4?
No. Claim 1 is a broader genus claim, and Claim 4 is a subset of enumerated examples.
References
(Only cited sources can be listed. No external sources were provided or cited for US 5,446,194 beyond the claim text you supplied.)
More… ↓
⤷ Start Trial
|
